January Therapeutics Adds Harvard’s Miles Miller to Scientific Advisory Board
SAN DIEGO – April 6, 2022 – January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the addition of Miles Miller,
Exploiting metabolic pathways to target tumors with effective therapeutics.
Our initial development programs are focused on oncology, specifically related to therapeutics.
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit
January Therapeutics is targeting cell-essential drivers of cancer which cannot be successfully drugged by chemistry alone. January’s technology exploits the dysregulated metabolic pathways in cancer and uses albumin to preferentially deliver drug to tumors while sparing healthy cells.
CEO
SAN DIEGO – April 6, 2022 – January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the addition of Miles Miller,
SAN DIEGO – March 7, 2022 January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the appointment of Thomas B. Broudy,
SAN DIEGO, March 3, 2021 January Therapeutics today announced the appointment of Christopher LeMasters to the Board of Directors. Mr. LeMasters brings more than 30
Sample Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod te mpor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel fa cilisis commodo viverra.